Novartis Surges on Restructuring Hopes Climbs to 291st in Dollar Volume

Novartis (NVS) surged 2.71% on October 1, 2025, with a trading volume of $0.44 billion—a 58.12% increase from the previous day—ranking it 291st among active stocks. The rally followed a strategic update highlighting long-term cost-saving initiatives and a restructuring of its pharmaceutical division. Analysts noted the move could streamline R&D pipelines and improve operational efficiency, potentially boosting investor confidence.

Recent developments include the company’s announcement of a partnership with a biotech firm to co-develop a novel oncology therapy. This collaboration, expected to reduce development risks, aligns with Novartis’s focus on high-impact therapeutic areas. The market reacted favorably to the news, perceiving it as a step toward strengthening its competitive edge in the biopharma sector.

To set up this back-test accurately, clarifications are required regarding the trading rules and parameters: 1. **Stock universe**: U.S.-listed common stocks on NYSE + NASDAQ? 2. **Ranking metric**: Raw share volume or dollar volume (volume × close price)? 3. **Entry/exit prices**: Close-to-close or enter at tomorrow’s open? 4. **Portfolio construction**: Equal-weight the 500 names daily? 5. **Costs & constraints**: Ignore transaction costs initially, or apply standard fees?

Once these details are confirmed, the back-test can proceed with a data-retrieval plan tailored to the specified criteria. The results will provide insights into the strategy’s historical performance under defined conditions.